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Recent studies have described chromosome 2p gain as a recurrent lesion in chronic lymphocytic leukemia
(CLL). We investigated the 2p gain and its relationship with common prognostic biomarkers in a prospec-
tive series of 69 clinical monoclonal B-cell lymphocytosis (cMBL) and 218 early stage (Binet A) CLL
patients. The 2p gain was detected by FISH in 17 patients (6%, 16 CLL, and 1 cMBL) and further character-
ized by single nucleotide polymorphism-array. Overall, unfavorable cytogenetic deletions, i.e., del(11)(q23)
and del(17)(p13) (P 5 0.002), were significantly more frequent in 2p gain cases, as well as unmutated status
of IGHV (P < 1 3 1024) and CD38 (P < 1 3 1024) and ZAP-70 positive expression (P 5 0.003). Furthermore,
2p gain patients had significantly higher utilization of stereotyped B-cell receptors compared with 2p nega-
tive patients (P 5 0.009), and the incidence of stereotyped subset #1 in 2p gain patients was significantly
higher than that found in the remaining CLLs (P 5 0.031). Transcriptional profiling analysis identified sev-
eral genes significantly upregulated in 2p gain CLLs, most of which mapped to 2p. Among these, NCOA1
and ROCK2 are known for their involvement in tumor progression in several human cancers, whereas
among those located in different chromosomes, CAV1 at 7q31.1 has been recently identified to play a criti-
cal role in CLL progression. Thus, 2p gain can be present since the early stages of the disease, particularly
in those cases characterized by other poor prognosis markers. The finding of genes upregulated in the
cells with 2p gain provides new insights to define the pathogenic role of this lesion. Am. J. Hematol. 88:24–
31, 2013. VC 2012 Wiley Periodicals, Inc.
Introduction
Chronic lymphocytic leukemia (CLL) is a clinically hetero-
geneous disease having an indolent course in most
patients who may survive for many years without treatment,
or showing an aggressive and rapidly progressive outcome
in others [1,2]. Although the current Rai [3] and Binet [4]
staging systems identify patients with high-risk disease,
they do not prospectively distinguish patients with poten-
tially evolving disease from those destined to remain stable
for decades.
A number of cellular and molecular markers help to clas-
sify CLL into biologically and clinically distinct subgroups,
and to predict the clinical course of the disease at diagno-
sis [5]. CLL patients with unmutated (UM) immunoglobulin
heavy chain variable (IGHV) region genes (>98% homol-
ogy to germline sequences), increased expression of the
CD38 cell surface antigen, or increased expression of the
70-kd zeta-chain T-cell receptor–associated protein kinase
(ZAP-70) experience a shorter therapy-free interval, and a
more aggressive behavior [6–8]. Specific recurrent chromo-
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somal abnormalities, traditionally detected by fluorescence
in situ hybridization (FISH), such as deletions at 13q14,
11q23, 17p13, 6q21-23, and trisomy 12, may also repre-
sent important independent biomarkers for disease pro-
gression and survival [9–13]. Whole genome analyses have
provided additional information on novel recurrent altera-
tions in CLL, such as gain of the short arm of chromosome
2 (2p). In particular, these studies focused on putative
oncogenes such as BCL11A, REL, and MYCN, located at
2p, as possible deregulated targets [14–24]. However, with
the exception of a very recent report [25], most of the avail-
able and representative studies investigating 2p gain have
been performed in quite heterogeneous and retrospective
series of patients encompassing various stages of the dis-
ease, making it difficult to ascertain the involvement and
role of 2p gain in the disease.
In this study, we attempted a comprehensive molecular
characterization of 2p gain in a large and representative
prospective series of clinical monoclonal B-cell lymphocyto-
sis (cMBL) and Binet stage A CLL patients. Detection of
the 2p gain was determined by FISH using locus specific
probes and was correlated with the major biological, molec-
ular, and genomic prognostic markers of the disease. Fur-
thermore, microarray analyses were carried out to charac-
terize the genomic profile of positive cases and transcrip-
tional profiles associated with 2p gain.
Methods
Patients. The 287 consecutive CLL patients included in this study
were enrolled in the Gruppo Italiano Studio Linfomi (GISL) O-CLL1
multicentre trial, that currently includes 463 cases (registered at Clini-
calTrials.gov, accession # NCT00917540). Written informed consent
was obtained from all patients in accordance with the declaration of
Helsinki and the study was approved by the local Ethics Review Com-
mittee (Comitato Etico Provinciale, Modena, Italy). The inclusion criteria
was a diagnosis of typical CLL in accordance with the 1996 National
Cancer Institute-sponsored Working Group (NCI-WC) guideline criteria
for CLL [26], based on morphological and phenotypical analyses (i.e.,
the co-expression of CD19, CD5, and CD23 and weak SmIg, and the
monotypical expression of k or k light chains by neoplastic cells). At
the time of enrollment, all patients had an absolute lymphocyte count
(ALC) of at least 5,000 3 109/L (range 5,000–100,000 3 109/L); 213
(77%) patients were at Rai 0 stage; 42 (15.1%) at stages I and 21
(7.6%) at stage II. On the basis of the new NCI-WC criteria [27],
among 213 Rai 0 patients subjected to immunophenotypic CD51/
CD191 analysis, 69 cases (32%) showed a clonal B-cell count <
5,000 3 109/L and were reclassified as CLL-like clinical MBL (cMBL)
[28]. Among cMBLs, 31 patients were males and 36 were females; the
mean and median age at diagnosis was 60 and 62 years, respectively
(range, 43–70). In CLL cases, the mean and median age was 59 and
60 years (range, 30–70 years), and 138 patients were males and 80
were females.
No conventional cytogenetic (G-banding) findings were available. The
median follow-up of this series was 30 months.
Sample preparation, molecular, and FISH analyses. Peripheral
blood mononuclear cells from CLL patients were collected within one
year from diagnosis and were isolated by Ficoll-Hypaque (Seromed,
Biochrom KG, Berlin, Germany) density-gradient centrifugation. For
FISH analysis and gene expression profiling experiments, CLL cells
were enriched by negative selection with the EasySep-Human B cell
enrichment kit without CD43 depletion (Stem Cell Technologies, Voden
Medical Instruments SPA, Milano, Italy) using the fully automated proto-
col of immunomagnetic cell separation with RoboSepTM (Stem Cell
Technologies).
The proportion of CD5/CD19/CD23 triple positive B cells in the sus-
pension was determined by direct immunofluorescence with antibodies
for CD19-FITC (BD Biosciences Pharmigen, San Jose`, CA), CD23-PE
(BD Biosciences), and CD5-PC5 (Beckman Coulter Immunotech, Mar-
seille, France). Sample purity of B-cells was greater than 90% for all
experiments.
CLL IGHV gene usage and mutation were determined as previously
described and the 98% homology cut-off value was used to discrimi-
nate the mutated (M) or unmutated (UM) IGHV configuration [29]; the
identification of distinct subsets with stereotyped BCRs was performed
as previously reported [30]. ZAP-70 and CD38 expression was exam-
ined by flow-cytometry as previously described [31,32] and cut-off
points were of 30 and 20%, respectively. The FISH study was per-
formed using the protocol provided by the manufacturer of the multi-
color probes LSI D13S25/LSI 13q34, LSIp53/CEP17, LSI ATM/CEP11,
and CEP12 (Vysis Inc., Downers Grove, IL) as previously described
[33], for the detection of 13q14, 17p13, and 11q22-q23 deletions and
trisomy 12, respectively. On the basis of single nucleotide polymor-
phism (SNP) arrays data previously reported by us [34], specific BAC
clones RP11-606L8 (BCL11A; 2p16.1) and RP11-368O18 (2p24.1),
selected from the University of California Santa Cruz (UCSC) Genome
Browser Database (http://genome.ucsc.edu/), were used for the identifi-
cation of 2p gain. FISH analyses were performed according to previ-
ously described protocols [35]. All contingency analyses were per-
formed by Fisher’s Exact test and differences between groups were an-
alyzed using the Mann-Whitney test. A P value < 0.05 was considered
significant for all statistical calculations.
SNP-array mapping analysis. Two hundred and fifty nanograms of
total genomic DNA were processed and hybridizations were performed
using Affymetrix GeneChip1 Human Mapping 250K NspI microarrays
according to manufacturer’s instructions (Affymetrix, Santa Clara, CA).
Images were acquired using Affymetrix GeneChip1 Operating System
version 1.4. The entire procedure for the copy number (CN) estimation
has been fully described previously [36]. Briefly, the raw data for indi-
vidual SNPs were extracted from CEL files and converted into signal
intensities using GTYPE 4.1 and Affymetrix Copy Number Analysis
Tool (CNAT 4.0.1) softwares using the Hidden Markov Model algorithm
with a genomic smoothing window set to 0. After the pre-processing,
piecewise constant estimates of the underlying local DNA CN variation
was calculated using the DNAcopy Bioconductor package, which looks
for optimal breakpoints using circular binary segmentation (CBS) [37],
and the median of the estimated profiles was scaled back to a nominal
multiplicity of two. After scaling, a k-means clustering algorithm was
used on the cumulative profile of all the data to determine the thresh-
olds for inferring discrete CN values were as follow: CN higher than 2.1
and 2.6 corresponded to gain and amplification whereas CN below 1.9
and 1.29 to loss and biallelic deletion, respectively.
Gene expression profiling and data analysis. Total RNA extraction,
preparation of DNA single-stranded sense target, hybridization to Gen-
eChip1 Gene 1.0 ST Array (Affymetrix) and scanning of the arrays (7G
Scanner, Affymetrix) were carried out according to manufacturer’s pro-
tocols. Log2-transformed expression values were extracted from CEL
files and normalized using NetAffx Transcript Cluster Annotations,
Release 32 (June 2011) and robust multi-array average (RMA) proce-
dure in Expression Console software (Affymetrix). The expression val-
ues of transcript cluster ID specific for loci representing naturally occur-
ring read-through transcriptions or mapped to more than one chromo-
somal location were summarized as median value for each sample.
Supervised analyses were performed as previously described (0% of
accepted median false discovery rate with 1,000 permutations) using
the Significant Analysis of Microarrays software (SAM version 4.00;
Excel front-end publicly available at http://www-stat.stanford.edu/tibs/
SAM/index.html) [38]. The functional annotation analysis on the
selected lists was performed by the Database for Annotation, Visualiza-
tion, and Integrated Discovery (DAVID) version 6.7 (U.S. National Insti-
tutes of Health at (http://david.abcc.ncifcrf.gov/) tool.
The genotyping and gene expression data are available at NCBI’s
Gene Expression Omnibus (GEO; http://www.ncbi.nlm.mih.gov/geo)
through GEO Series Accession no. GSE 38618.
Real-time quantitative polymerase chain reaction. ROCK2 and
CAV1 expressions were analyzed in purified CD191 cells by means of
real-time quantitative RT-PCR (Q-RT-PCR). Total RNA was converted
to cDNA using M-MLV reverse transcriptase (Invitrogen). Inventoried
TaqMan Gene Expression Assays (Hs00178154_m1 for ROCK2 and
Hs00971716_m1 for CAV1) and the TaqMan Fast Universal Master Mix
were used according to manufacturer’s instructions (Applied Biosys-
tems, Foster City, CA). UBC TaqMan Gene Expression Control
(Hs00824723_m1) (Applied Biosystems) was used as the internal con-
trol. The measurement of gene expression was performed using the
Applied Biosystems StepONE Real-Time PCR System. All the samples
were run in duplicate. Data were expressed as 22DCt (Applied User
Bulletin No. 2).
Results
Identification of 2p gain in cMBL and CLL patients
We investigated the occurrence of 2p gain in a series of
287 newly diagnosed, untreated CLL cases included in the
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Italian multicentre prospective clinical trial O-CLL1. The
major patients’ features are reported in Table I, whereas
the biological and molecular characteristics of patients har-
boring the 2p gain are summarized in Tables I and II. Gain
of 2p was detected by FISH in 17 patients (6%) with a me-
dian percentage of positive nuclei of 60% (range, 7–100%).
The number of additional copies was one in all the positive
cases. Both FISH probes detected chromosomal gains in
all but two cases (CA0058 and PG0065) in which only the
centromeric probe (RP11-606L8) was gained. We observed
the 2p gain as a single aberration in six cases. In the
remaining cases, 2p gain was associated with trisomy 12
or 13q monoallelic deletion in two and three patients,
respectively; with 17p13 and 13q monoallelic deletions in
two cases; with 11q23 and 13q monoallelic deletions in
three cases; with a 11q23 and 13q biallelic deletions in one
case. Overall, there was a higher prevalence of unfavorable
cytogenetic deletions, i.e., del(11)(q23) and del(17)(p13) (P
5 0.002, Table I) in 2p positive patients. Interestingly, only
three of the 2p positive patients were female, confirming
previous findings of a male gender predominance in poor
prognosis patients [7].
Notably, UM IGHV status and ZAP-70 and CD38 positive
expression were significantly more frequent in 2p positive
cases compared to 2p negative patients (17/17, 100%; 16/
17, 94% and 14/17, 82%, respectively) (Table I). The fre-
quency of 2p gain in cMBLs (1/69; 1.4%) was lower than
that of CLL patients of our series (16/207, 7.7%) as well as
of the Rai 0 cases (12/144, 8.3%), albeit not significant. A
significantly more frequent utilization of stereotyped BCR
was observed in CLL with 2p gain compared with the nor-
mal ones (10/16, 62% vs. 76/263, 29%) (P 5 0.009,
Table I). Interestingly, the utilization of stereotyped subset
#1 was significantly more frequent in 2p positive patients
(3/10, 30%) than that of all the other stereotyped CLLs (4/
76, 5%) (P 5 0.031, Table I), whereas no statistically signif-
icant association was demonstrated with IGHV gene usage
(data not shown).
Finally, we did not find any significant difference in the
time to first treatment between the 2p positive and 2p neg-
ative CLLs (P 5 0.320). This finding was also confirmed af-
ter exclusion of cMBL cases from the analysis (P 5 0.480)
(Supporting Information Fig. 1).
SNP-array analysis of CLLs with 2p gain
The genomic profile was investigated in 10 CLL patients
with 2p gain. The lesion was confirmed in all but one case
(LL0130), which case showed a very low proportion of cells
carrying the alteration (7%), in all likelihood not detectable
by microarray technology. Figure 1A shows the extension
of the 2p gain in the 9 patients. Specifically, the gain
TABLE I. Biological and Clinical Characteristics of the 69 MBL and 218 Binet
Stage A CLLs Included in the Study (Significance Assessed by Fisher’s
Exact Test)
Characteristics
All patients
(n 5 287)
2p gain
(n 5 17)
2p normal
(n 5 270) P
Age (years)
Median 61 59 61 nsa
Range (30–71) (30–71) (33–71)
Sex
Female 120 3 117 P 5 0.043
Male 167 14 153
MBLb 69 1 68
Rai
0 144 12 132
I 42 4 38 ns
II 21 / 21
IGHV homology
98% 93 17 76 P <1 3 1024
<98% 186 / 186
Stereotyped HCDR3
Yes 86 10 76 P 5 0.009
No 193 6 187
Subset #1
Yes 7 3 4 P 5 0.032
No 79 7 72
CD38
20% 74 14 60 P <1 3 1024
<20% 209 3 206
ZAP70
30% 173 16 157 P 5 0.004
<30% 111 1 110
FISH
Normal 92 6 86
del13q14 (alone) 156 (137) 9 (3) 147 (134) P 5 0.017c
112 33 2 31 ns
del11q23 18 4 14 P 5 0.016
del17p13 8 2 6 ns
Unfavorable aberrations
(del11q23 or del17p13)
26 6 20 P 5 0.002
a
Wilcoxon rank-sum test.
b
MBL, monoclonal B lymphocytosis.
c
Calculated on del13q14 as unique lesion.
TABLE II. Biological and Molecular Characteristics of 17 CLL Patients Harboring 2p Gain
ID Age Sex 12p 112 del(17) del(11) del(13) CD38 ZAP-70 IGHV IGHV gene use Subset
CA0058 53 Ma 45.5b 2 2 2 2 2 1 UMc IGHV1–69*01 3#
CG0038 47 M 100 2 2 2 2 1 1 UM IGHV3–15*01 NSd
CP0104 57 M 70 2 2 2 97 2 1 UM IGHV3–49*03 NS
DA0094 63 M 81 2 100 2 100 1 1 UM IGHV3–30*01 7#
GP0171 48 M 60 2 2 100 100 2 1 UM IGHV3–23*01 22#
LL0130 53 M 7 2 2 99 100 1 1 UM IGHV1–69*01 NS
MB0065 59 M 100 2 2 2 2 1 1 UM IGHV3–30*02 32#
NM0156 63 Fe 35 2 2 2 2 1 2 UM IGHV5–51*01 38#
PB0376 70 M 14 100 2 2 2 1 1 UM IGHV1–3*01 1#
PG0028 59 M 35 2 36 2 24 1 1 UM IGHV1–3*01 1#
SR0112 64 M 10 2 2 2 2 1 1 UM IGHV3–21*01 NS
TF0001 30 M 26 100 2 2 2 1 1 UM IGHV4–34*01 NS
VM0107 57 F 100 2 2 97 99 1 1 UM IGHV1–69*01 5#
VG00442 65 M 52 2 2 2 50 1 1 UM IGHV4–59*07 32#
RG0443 62 M 100 2 2 100 98f 1 1 UM IGHV1–2*04 1#
MG0449 64 F 92 2 2 2 2 1 1 UM IGHV4–59*01 NS
PG0065 65 M 77 2 2 2 100 1 1 UM IGHV5–51 NS
a
M, male.
b
The percentage of positive nuclei was indicated.
c
UM, unmutated.
d
NS, not stereotyped.
e
F, female.
f
Positive for 13q14 biallelic deletion.
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involved the whole short arm of chromosome 2 in six
patients (TF0001, NM0156, MB0065, VM0107, CP0104,
DA0094); most part of the short arm in two cases (GP0171
and PG0028); and a smaller region (31.7 Mb) encompass-
ing cytobands 2p16.1-p11.1 in a single patient (CA0058).
The minimal gained region was 10.2 Mb in length from
2p16.1 to p14 and included the two putative oncogenes
BCL11A and REL. The MYCN gene was involved in all
but one case (CA0058) (Fig. 1A). SNP-array results
were fully concordant with FISH analyses in detecting the
major genetic lesions except in case PG0028 which
carried a 13q monoallelic deletion. This was present in
only 24% of cells and could be observed solely by FISH
(Fig. 1B and Supporting Information Table I for more
details).
Transcriptional signature associated with the 2p gain
Gene expression profiling was performed in the 30 cMBL
and 106 Binet stage A CLL patients including 12 cases
with 2p gain. The major genetic lesions and IGHV muta-
Figure 2. A: Supervised analysis of 2p gain versus 2p normal UM CLLs not showing trisomy 12. By means of SAM supervised analysis at relatively high stringent
conditions (q-value 5 0) 18 probes resulted differentially expressed. Information about IGHV mutational status (’’1‘‘ 5 M, ‘‘2‘‘ 5 UM), CD38, ZAP-70, chromosome
12 trisomy, chromosome 17, 11, and 13 deletions, and 2p gain (‘‘1’’ 5 positive, ’’2’’ 5 negative) are included alongside the patient ID. The color scale bar represents the
relative gene expression changes normalized by the standard deviation, and the color changes in each row represent gene expression relative to the mean across
the samples. The gene symbols are indicated. B: Q-RT-PCR validation of the microarray expression data. The correlation coefficients of expression levels were assessed
for ROCK2 and CAV1 genes and are shown in the chart. Both the microarray and Q-RT-PCR data have been scaled in the range 0–1.
Figure 1. A: Chromosome 2p gain pattern in 9 CLL patients detected by SNP-array, as assessed by means of GeneChip1 Human Mapping 250K NspI. Common region
of gain of 2p is indicated by dashed vertical lines. Each horizontal red line indicates the range of gain of each CLL patient. Physical positions of FISH clones RP11-
368O18 and RP11-606L8 used to perform the 2p gain analysis and the localization of ACP1, ROCK2, MYCN, NCOA1, ALK, BCL11A, and REL genes are also indicated.
B: Heatmap of significantly altered DNA copy number in 9 CLL samples. Horizontal axis: chromosome localization. The dashed lines represent the location of the centro-
meres. Blue: loss; white: normal CN; red: DNA gain (three copies).
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tional status, CD38 and ZAP-70 expression of the 124
patients without 2p gain are shown in Supporting Informa-
tion Figure 2A. Supervised analysis revealed 96 differen-
tially expressed genes between 2p positive and 2p negative
patients; the majority of these genes (94%) were up-regu-
lated in 2p positive patients, and 21 of them mapped at the
short arm of chromosome 2 (Supporting Information Fig.
2A). When a multiclass supervised analysis was performed
comparing UM, M and 2p positive patients, we observed a
strong similarity between the transcription pattern of UM
and 2p positive patients (Supporting Information Fig. 2B).
Consequently, to avoid bias factors introduced by the fact
that all the 2p positive patients analyzed by gene expres-
sion were UM and did not harbor trisomy 12, a supervised
analysis comparing twelve 2p positive and thirty-three 2p
normal UM CLLs without trisomy 12 was carried out (Fig.
2A). There were differences in the expression of 18 genes,
all of which were upregulated in 2p gained patients and all
but two (CAV1 and PSD3) mapping at 2p (see Table III).
The ROCK2 and CAV1 genes were selected for Q-RT-
PCR validation. The Q-RT-PCR analyses were performed
on a panel including 10 2p positive and 30 2p negative
samples from our dataset. The correspondence between
the microarray and Q-RT-PCR data were evaluated by
assessing the linear correlation coefficients of the expres-
sion levels determined by the two analyses: the coefficients
were 0.84 for the ROCK2 probe and 0.92 for the CAV1
probe, thus indicating almost complete concordance for
both genes (Fig. 2B).
Discussion
Previous retrospective studies based on FISH, compara-
tive genomic hybridization (aCGH) and SNP array identified
2p gain as a recurrent alteration in CLL associated with
advanced Binet stage, UM status of IGHV gene and 17p13
deletion [12,14–22,24,39–42].
In this study carried out on a cohort of cMBL and early
stage CLL, 2p gain was detected in a fair proportion of cases
(6%), indicating that this lesion may appear since the early
stages. Interestingly, 2p gain was detected as the sole cyto-
genetic lesion in six cases: this is unlike most reports
[14,15,19,20,39] where 2p gain was always detected to-
gether with the most frequent cytogenetic lesions. In the
remaining 11 cases, 2p gain was significantly associated
with the presence of 11q deletion (P 5 0.016). Similar result
was also reported by Rinaldi et al. [23].
The choice of investigating early cases has conceivably
facilitated the detection of cases with 2p gain only, since a
number of cytogenetic changes appear later during the dis-
ease course and it is thus not surprising that different cytoge-
netic changes coexist in advanced stages as well as in cases
characterized by unfavorable prognostic markers [40]. The
finding of 2p gain in early stages of disease in the absence of
other major lesions may indicate a possible role for 2p gain in
disease progression. Furthermore, it should be noted that in
some patients the 2p gain was detected in a relatively small
fraction of nuclei compared to the percentage of leukemic
cells carrying additional rearrangements. Taken together,
these findings further support the suggestion that 2p gain
may represent both an early lesion in some CLL patients or a
secondary alteration associated with concurrent abnormal-
ities in others. The association with unfavorable prognostic
factors did not reflect on the risk of progression in our cohort,
where no significant difference between 2p gain and 2p nor-
mal CLLs were evidenced in the time to first treatment. How-
TABLE III. Functional Annotations of the 18 Overexpressed Genes in 2p Gained Patients Ordered According to SAM Score(d)
Gene title
Gene
symbol Localization
Biological process
description Score(d)
Fold
change
Rho-associated, coiled-coil
containing protein kinase 2
ROCK2 2p24 Cytokinesis, cytoskeleton organization, r
egulation of cell cycle process,
regulation of cell division, protein
amino acid phosphorylation
4.17 1.73
Striatin, calmodulin binding protein STRN 2p22-p21 Regulation of cell proliferation,
Wnt receptor signaling pathway,
cell-cell junction organization
4.11 1.33
Caveolin 1, caveolae protein, 22kDa CAV1 7q31.1 Microtubule cytoskeleton, cellular homeostasis,
cell communications, regulation of
vesicle-mediated transport, protein complex
assembly, regulation of protein kinase
cascade, cell proliferation,
regulation of anti-apoptosis
4.09 1.89
Nuclear receptor coactivator 1 NCOA1 2p23 Positive regulation of transcription, DNA-dependent,
intracellular signaling cascade,
steroid hormone receptor signaling pathway
4.07 1.33
RAB1A, member RAS oncogene family RAB1A 2p14 Regulation of transcription, DNA-dependent, intracellular
signaling cascade, vesicle-mediated transport
3.83 1.34
Isoamyl acetate-hydrolyzing esterase
1 homolog (S. cerevisiae)
IAH1 2p25.1 Lipid catabolic process 3.81 1.28
Galectin-related protein HSPC159 2p14 Carbohydrate binding 3.76 1.64
Pleckstrin and Sec7 domain
containing 3
PSD3 8pter-p23.3 Regulation of Ras protein signal transduction, regulation of
small GTPase mediated signal transduction
3.73 2.16
SMEK homolog 2, suppressor of mek1
(Dictyostelium)
SMEK2 2p16.1 Microtubule organizing center 3.71 1.33
tRNA methyltransferase 61 homolog
B (S. cerevisiae)
TRMT61B 2p23.2 RNA methylation, tRNA metabolic process 3.69 1.42
Dystrobrevin, beta DTNB 2p24 Metal ion binding 3.65 1.33
Lysine-rich coiled-coil 1 KRCC1 2p11.2 – 3.65 1.53
Phosphatidylinositol glycan anchor
biosynthesis, class F
PIGF 2p21-p16 GPI anchor biosynthetic process, phospholipid biosynthetic process 3.58 1.85
Neuroblastoma amplified sequence NBAS 2p24 – 3.57 1.27
Chaperonin containing TCP1,
subunit 4 (delta)
CCT4 2p15 Protein folding 3.50 1.30
Pumilio homolog 2 (Drosophila) PUM2 2p22-p21 Regulation of translation, regulation of cellular protein metabolic process 3.46 1.21
Aftiphilin AFTPH 2p14 Protein localization, protein transport 3.41 1.26
Family with sequence similarity 82,
member A1
FAM82A1 2p22.2 – 3.40 1.46
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ever, we cannot exclude that different prognostic information
could be obtained with longest follow-up.
Of note is also the finding that the proportion of cases
with 2p gain was higher than that (2–3%) recently reported
by Deambrogi et al. [15] in their retrospective series of
newly diagnosed CLLs investigated by FISH. Most likely,
this discrepancy could be due to the fact that our analyses
were performed on highly purified B cells that definitely
improved the ability of FISH to detect the alteration even in
small subclones (see Table II). In addition, there was an
association with certain stereotyped BCRs and in particular
with subset #1, which characterizes cases with more unfav-
orable course [30]. The reasons for this association are not
easily apparent. However, based upon observations that
unmutated CLL cells are more easily stimulated by signals
delivered by the BCR, express surface activation markers
and have a more active in vivo turn-over [43], it can be
speculated that the more intense proliferation of the cells
from this CLL subgroup facilitates the accumulation of 2p
gain as well as of other cytogenetic abnormalities. Overall,
our findings confirm the evidence that 2p gain is associated
even at early stage disease with a subgroup of CLLs char-
acterized by negative biomolecular prognostic markers; this
evidence is further supported by the almost absence of 2p
gain in cMBL. The low frequency of 2p gain in cMBL also
could be explained based upon differences in clonal expan-
sion capacities. Indeed, cMBL with unmutated BCR are
more likely to progress rapidly into full blown CLL.
Although previous studies suggested various genes
(REL, BCL11A, MYCN, ALK, and more recently ACP1)
[14–22,24] as potential targets of the 2p gain, no firm data
supporting this notion are available. We used a microarray
technology approach in order to characterize the putative
critical region of 2p gain as well as the deregulated genes
in the context of the chromosomal alteration. The minimally
duplicated region in our cohort as assessed by SNP-array
showed that three of the putative target genes, BCL11A,
REL, and MYCN, were involved in all but one case, which
was specifically devoid of the MYCN gain. However, no dif-
ferences in BCL11A, REL, and MYCN expression levels
between 2p gain positive and 2p negative patients was
observed, nor differences of ALK gene expression were
noticed. Particularly, we were not able to detect a signifi-
cant up-regulation of the MYCN gene as described by
others based on Q-RT-PCR or microarray [14,24]: the lim-
ited number of 2p positive CLLs, the higher prevalence of
clinical advanced stages in those previous studies as well
as a different generation array could explain this discrep-
ancy. Finally, the ACP1 gene recently described by Dequin
et al. [20] as commonly gained (25%) in CLL, was gained
in all but one case analyzed by SNP-array.
This data demonstrate that a remarkable gene dosage
effect can be associated with the 2p gain and that novel
genes can be up-regulated as a possible consequence of
the 2p gain. Among these we should mention NCOA1 (nu-
clear receptor coactivator (1), a transcriptional coactivator
belonging to the SRC family which is deregulated in breast
and prostatic cancer and may potentiate gene expression
by acting as a coactivator for nuclear hormone receptors
and other transcription factors (TF) [44–55]; and ROCK2, a
serine/threonine kinase member of the Rho pathway,
involved in cell adhesion, migration, invasion, and mitosis
[56–59], which may be a potential therapeutic target in
human cancer cells and animal models [60–68].
Among the genes which do not map at 2p but which are
upregulated in 2p gained CLL patients, CAV1 (caveolin-1),
mapping to 7q31.1, could be of potential relevance. CAV1
is the major coat protein of caveolae, membrane invagina-
tions involved in multiple cellular functions including molec-
ular transport, cell adhesion, and signal transduction
[69,70]. CAV1 has been identified as a tumor suppressor
gene in some cancers, whereas in other its up-regulation
promotes cell survival, adhesion, and migration [71,72].
CAV1 expression is elevated in multiple malignancies
including breast and prostate cancer, myeloma, thyroid car-
cinoma, colon, and lung cancer [73–78]. Furthermore, Joshi
et al. [79] defined a feedback loop between Rho/ROCK,
Src, and phosphorylated CAV1 in tumor cell protrusions,
identifying a novel function for CAV1 in tumor metastasic
spreading. More interestingly perhaps, Gilling et al. [80]
recently described a critical role for CAV1 in CLL progres-
sion involving CLL-tumor microenvironment interaction,
specifically immune synapse formation, migration, and pro-
liferation.
Overall, to the best of our knowledge, this is the first
comprehensive report providing evidence that 2p gain is an
early recurrent chromosomal abnormality in a large pro-
spective series of untreated early-stage CLLs. We identified
novel genes found to be modulated in the context of 2p
gain which may deserve further investigation to clarify its
pathogenetic role in the disease.
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